Released Aug 14, 2025, after the close
10-Q filed Aug 14, 2025, 45 days after period end · 0001683168-25-006159
Q2 2025 · 10-Q
Revenue—
Net Income-$5.95M-$5.95M N/M vs Q2 2024N/M vs Q1 2025
EPS Diluted-$0.30-$0.30 N/M vs Q2 2024N/M vs Q1 2025
Operating Income-$5,968,877N/M
Operating Cash Flowderived-$4,173,761N/M
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|
| Net Income | -$5.95M | -$6.57M | -$5.52M |
| EPS Diluted | -$0.30 | -$4.20 | -$3.88 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Actuate Therapeutics, Inc. · CIK 1652935 · Engraved from SEC EDGAR